A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer

Karen Kelly, N. Mikhaeel-Kamel, Z. Pan, J. Murphy, S. Prindiville, Jr Bunn P.A.

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)3474-3479
Number of pages6
JournalClinical Cancer Research
Volume6
Issue number9
StatePublished - 2000
Externally publishedYes

Fingerprint

gemcitabine
Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Antimetabolites
Survival
Maximum Tolerated Dose
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. / Kelly, Karen; Mikhaeel-Kamel, N.; Pan, Z.; Murphy, J.; Prindiville, S.; Bunn P.A., Jr.

In: Clinical Cancer Research, Vol. 6, No. 9, 2000, p. 3474-3479.

Research output: Contribution to journalArticle

Kelly, K, Mikhaeel-Kamel, N, Pan, Z, Murphy, J, Prindiville, S & Bunn P.A., J 2000, 'A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer', Clinical Cancer Research, vol. 6, no. 9, pp. 3474-3479.
Kelly, Karen ; Mikhaeel-Kamel, N. ; Pan, Z. ; Murphy, J. ; Prindiville, S. ; Bunn P.A., Jr. / A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 9. pp. 3474-3479.
@article{09ef3a652d0144dba4658e591fb90645,
title = "A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer",
abstract = "Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.",
author = "Karen Kelly and N. Mikhaeel-Kamel and Z. Pan and J. Murphy and S. Prindiville and {Bunn P.A.}, Jr",
year = "2000",
language = "English (US)",
volume = "6",
pages = "3474--3479",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer

AU - Kelly, Karen

AU - Mikhaeel-Kamel, N.

AU - Pan, Z.

AU - Murphy, J.

AU - Prindiville, S.

AU - Bunn P.A., Jr

PY - 2000

Y1 - 2000

N2 - Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.

AB - Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0033817994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033817994&partnerID=8YFLogxK

M3 - Article

C2 - 10999731

AN - SCOPUS:0033817994

VL - 6

SP - 3474

EP - 3479

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -